Help
Options
Didn't know it?
click below
click below
Knew it?
click below
click below
Don't Know
Remaining cards (0)
Know
retry
shuffle
restart
0:00
Embed Code - If you would like this activity on your web page, copy the script below and paste it into your web page.
Normal Size Small Size show me how
Normal Size Small Size show me how
Heart Failure/Angina
Drugs for HF and Angina
| Drug | Indication | Pharmacokinetics | Adverse Effects | Notes | Drug Interactions |
|---|---|---|---|---|---|
| ACE Inhibitors | Considered cornerstone of HF therapy. Block production of angII, dec. release of aldosterone, suppress degradation of kinins (ARBs don't do this). SO they improve hemodynamics and favorably alter cardiac remodeling | hemodynamic benefits: arteriolar dilation improves regional blood flow in kidneys,promoting excretion of Na and H2O; Reducing afterload increases CO and SV;Venous dilation reduces venous pressure_>red. pulmonary congestion, periph. edema, preload and card | Hypotension 2/2 arteriolar dilation; cough (bradykinin acc. 2/2 inhibition of ACE); angioedema; hyperkalemia 2/2 dec. aldosterone release; fetal injury; renal failure with low GFR | in absence of contraindications, all HF should get ACEI | |
| ARB | improve LV ejection fraction, reduce HF symptoms, increase exercise tolerance, decrease hosp, enhance QOL, reduce mortality | hypotension, angioedema, renal failure, fetal harm | *do not increase levels of kinins, like AECI do, so effects on cardiac remodeling less favorable; so use for HF pts who cant tolerate ACEI (d/t cough) | ||
| Aldosterone Antagonists (eplerenone, spironolactone) | reduce s/s, decrease hosp, prolong life in pts w/HF | primary is hyperkalemia (risk increased by renal impairment and ACE/ARB use) measure baseline and monitor | use if pts have severe symptoms | ||
| B Blockers (HF) | can improve LV ejection fraction, increase exercise tolerance, slow progression of HF, reduce hosp, prolong survival | fluid retention, worsening of HF, fatigue, hypotn, bradycardia or heart block (d/t reduction in contractility) | since blockade of cardiac B1 receptors reduces contractility, doses must be low initially and increased gradually,and used w/ care | ||
| Digoxin (only cardiac glycoside approved in US) | HF and control of dysrhythmias: +inotropic agent, increasing CO, MOA:inhibits Na-K-ATPase,promoting Ca accumulation w/in myocytes, augmenting contractile force | absorption can vary w/ pharm company; crosses placenta;elim. primarily renally, so alterations in renal fxn can have profound impact on dig levels | low K->digoxin toxicity, high K->low therapeutic response (s/s of toxicity: altered HR or rhythm, GI or visual disturbances) | (when used for HF, can reduce s/s, increase exercise tolerance, and decrease hosp., but the drug does not prolong life,so consid. 2nd line agent) Therapeutic drug levels for HF:0.5-0.8 ng/ml, toxic>2ng/ml (narrow index) | diuretics (hypokelmia->toxicity); ACEI/ARBs (hyperkalemia->dec. dig effects); sympathomimetics (additive inotropic effect);Amiodarone (dog tox due to inhibiton of p-glycoprotein); St. John's Wort; Quinidine; Verapimil |
| Sodium Nitroprusside (nitropress) | short term therapy of severe refractory HF | profound hypotn, so monitor BP continuously | acts rapidly to dilate arterioles and veins; A dilation reduces afterload, increasing CO; V dilation reduces venous pressure, decreasing pulmonary and peripheral congestion | ||
| Nitrates (NTG, isosorbide mononitrate, isosorbide dinitrate) | Act directly on vascular smooth muscle to promote vasodilation; stable angina: NTG dec. pain by decreasing cardiac O2 demand, by dilating veins, NTG dec. venous return to heart dec vent. filling, decrease in preload, decreases demand; Variant Angina: goal | absorption:highly lipid soluble and crosses membranes w/ease;metabolism:nitrates undergo rapid inactivation by hepatic enzymes;tolerance:excessive use,esp. w/high dose and uninterrupted therapy.SO, use lowest effective dose, and using long-acting formulat | headache, ortho hypotn, reflex tachy | long acting preparations should be d/c slowly to prevent vasospasms | |
| B Blockers (angina) | reduce cardiac O2 demand by blockade of B1 receptors, decreasing HR and contractility; modest reductions in afterload, and slowing HR, increases time in diastole, can help increase O2 supply | effects on CNS: depression, bizarre dreams, insomnia, sexual dysfunction, mask signs of hypoglycemia | In pts taking vasodilators, BB can provide the additional benefit of blunting reflex tachy;should not be withdrawn abruptly,can increase angina intensity and even precipitate MI; NOT effective against Var.angina&should not be used in pts w/decompensated H | ||
| CCB (verapamil, diltiazem, nifedipine-dihydropyridine) | arteriolar dilation and reduction of afterload; relax coronary vasospasm; D&V can block CC in heart | induce reflex tachy (nifedipine); V&D are cardiosuppressors, so use cautiously in pts with BB, bradycardia, HF or AV block | used for both var (increase o2 supply->relax coronary artery vasospasm) and stable angina (decrease O2 demand->decrease afterload) | ||
| Ranolazine | treatment of chronic angina | MOA not understood, but inhibits late Na current, reducing Na-induced Ca overload in myocytes | prolongs QT interval, may increase risk of arrythmias; dizziness, constipation, headache, nausea | NOT first line treatment | metabolized through CYP3A4 inhibitors, and is a substrate for P-glycoprotein, veramipil and diltiezam should not be co-administered, since can lead to ranolazine toxicity |
| Diuretics | First line therapy for pts with signs of FVE: decrease VP,AP(afterload),Pulmonary and peripheral edema,and cardiac dilation | Do not overdiurese pt ->FVD, rx according to level of edema | |||
| Thiazides | 1.don't diurese as much as loops 2. used for LT therapy of HF when edema is not too great 3. cannot be used if CO too low (GFR low) 4.principal adverse effect is hypokalemia (increasing risk of digoxin-induced dysrh) | ||||
| Loop/High Ceiling Diuretics (furosemide) | 1. produce profound diureses 2. can be used if GFR is low 3.preferred if HF is severe 4.can also cause hypokalemia (digoxin-induced dysrh) 5.severe hypotn 2/2 excessive volume reduction | ||||
| K Sparing Diuretics | 1. used primarily to maintain K levels 2.produce scant diuresis | use caution when combined with ACE/ARBs |
Created by:
jellyfishh
Popular Nursing sets